Skip to main content

Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda

Buy Article:

$34.78 + tax (Refund Policy)

SETTING: Kiboga district, a rural area in Central Uganda.

OBJECTIVE: To assess the cost and cost-effectiveness of community-based care for new smear-positive pulmonary tuberculosis patients compared with conventional hospital-based care.

METHODS: Costs were analysed from the perspective of health services, patients, and community volunteers in 1998 US$, using standard methods. Cost-effectiveness was calculated as the cost per patient successfully treated.

FINDINGS: The cost per patient treated for new smear-positive patients was $510 with the conventional hospital-based approach to care ($419 for the health system and $91 for patients), and $289 with community-based care ($227 for health services, $53 for patients and $9 for volunteers). Important new costs associated with community-based care included programme supervision ($18 and $9 per patient at central and district levels, respectively) and training ($18 per patient). The cost per patient successfully treated was $911 with the hospital-based strategy and $391 with community-based care, reflecting both lower costs and higher effectiveness (74% vs. 56% successful treatment rate) with community-based care. Length of hospital stay fell from an average of 60 to 19 days.

CONCLUSION: There is a strong economic case for the implementation of community-based care in Uganda.

Keywords: Uganda; community-based care; cost effectiveness

Document Type: Regular Paper

Affiliations: 1: Makerere University, Kampala, Uganda 2: Stop TB Department, World Health Organization, Geneva, Switzerland 3: National TB and Leprosy Control Programme, Kampala, Uganda 4: World Health Organization, Kampala, Uganda

Publication date: 01 September 2003

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content